SEARCH

SEARCH BY CITATION

References

  • Abercrombie E. D., Bonatz. A. E. and Zigmond M. J. (1990) Effects of 1-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 525, 3644.
  • Ahlskog J. E. and Muenter M. D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16, 448458.
  • Ahn S., Cheng C., Phillips A. G. and Lee C. S. (2004) Reversal of the dopamine transporter in the severely 6-OHDA lesioned striatum with chronic L-DOPA treatment: a Reverse Dialysis study with GBR 12909. In: Abstract Viewer/Itinerary Planner, Volume Online, P. Program no. 562.563. Society for Neuroscience, Washington, DC.
  • Alonso F., Zamarbide I., Alegre M., Rodriguez-Oroz. M. C., Guridi J., Manrique M., Valencia M., Artieda J. and Obeso J. A. (2006) Slow oscillatory activity in the subthalamic nucleus and levodopa-induced dyskinesias in Parkinson's Disease. Brain in press.
  • Andersson M., Hilbertson A. and Cenci M. A. (1999) Striatal fosB expression is causally linked with 1-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis 6, 461474.
  • Andersson M., Konradi C. and Cenci M. A. (2001) cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 21, 99309943.
  • Andersson M., Westin J. E. and Cenci M. A. (2003) Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J. Neurosci. 17, 661666.
  • Arai R., Karasawa N., Geffard M. and Nagatsu I. (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195, 195198.
  • Aubert I., Guigoni C., Hakansson K. et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57, 1726.
  • Bara-Jimenez. W., Bibbiani F., Morris M. J., Dimitrova T., Sherzai A., Mouradian M. M. and Chase T. N. (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20, 932936.
  • Betarbet R., Turner R., Chockkan V., DeLong M. R., Allers K. A., Walters J., Levey A. I. and Greenamyre J. T. (1997) Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17, 67616768.
  • Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C. and Sokoloff P. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med. 9, 762767.
  • Blanchet P. J., Allard P., Gregoire L., Tardif F. and Bedard P. J. (1996) Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J. Neurol. Sci. 23, 189193.
  • Braak H., Ghebremedhin E., Rub U., Bratzke H. and Del Tredici K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121134.
  • Bravi D., Mouradian M. M., Roberts J. W., Davis T. L., Sohn Y. H. and Chase T. N. (1994) Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann. Neurol. 36, 2731.
  • Brotchie J. M. (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20, 919931.
  • Brown W. D., Taylor M. D., Roberts A. D., Oakes T. R., Schueller M. J., Holden J. E., Malischke L. M., DeJesus O. T. and Nickles R. J. (1999) FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53, 12121218.
  • Calabresi P., Pisani A., Mercuri N. B. and Bernardi G. (1996) The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19, 1924.
  • Calabresi P., Saiardi A., Pisani A., Baik J. H., Centonze D., Mercuri N. B., Bernardi G. and Borrelli E. (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J. Neurosci. 17, 45364544.
  • Calon F., Rajput A. H., Hornykiewicz. O., Bedard P. J. and Di Paolo T. (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis 14, 404416.
  • Carlsson T., Winkler C., Burger C., Muzyczka N., Mandel R. J., Cenci A., Bjorklund A. and Kirik D. (2005) Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128, 559569.
  • Carta M., Lindgren H., Lundblad M., Stancampiano R., Fadda F. and Cenci M. A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 17181727.
  • Cenci M. A. (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23, 105109.
  • Cenci M. A., Lee C. S. and Bjorklund A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J. Neurosci. 10, 26942706.
  • Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P. and Bernardi G. (1999) Unilateral dopamine denervation blocks corticostriatal LTP. J. Neurophysiol. 82, 35753579.
  • Cepeda C., Colwell C. S., Itri J. N., Chandler S. H. and Levine M. S. (1998) Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J. Neurophysiol. 79, 8294.
  • Chase T. N. (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50, S17S25.
  • Chase T. N. and Oh J. D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86S91.
  • Crocker S. J., Morelli M., Wigle N., Nakabeppu Y. and Robertson G. S. (1998) D1-Receptor-related priming is attenuated by antisense-meditated ‘knockdown’ of fosB expression. Brain Res. Mol Brain Res. 53, 6977
  • Di Monte D. A., McCormack A., Petzinger G., Janson A. M., Quik M. and Langston W. J. (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15, 459466.
  • Dunah A. W., Wang Y., Yasuda R. P., Kameyama K., Huganir R. L., Wolfe B. B. and Standaert D. G. (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol. 57, 342352.
  • Erickson J. D., Schafer M. K., Bonner T. I., Eiden L. E. and Weihe E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl Acad. Sci. U S A 93, 51665171.
  • Fahn S. (2000) The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47, S2S9; discussion S9–11.
  • Fahn S. (2003) Description of Parkinson's disease as a clinical syndrome. Ann. N Y Acad. Sci. 991, 114.
  • Fearnley J. M. and Lees A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 22832301.
  • Finkelstein D. I., Stanic D., Parish C. L., Tomas D., Dickson K. and Horne M. K. (2000) Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97, 99112.
  • Fiorentini C., Gardoni F., Spano P., Di Luca M. and Missale C. (2003) Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J. Biol. Chem. 278, 20 19620 202.
  • Fiorentini C., Rizzetti M. C., Busi C., Bontempi S., Collo G., Spano P. and Missale C. (2006) Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol. 69, 805812.
  • De La Fuente-Fernandez. R. Lu J. Q. Sossi V. Jivan S. Schulzer M. Holden J. E. Lee C. S. Ruth T. J. Calne D. B. and Stoessl A. J. (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol 49, 298303.
  • De La Fuente-Fernandez. R. Schulzer M. Mak E. Calne D. B. and Stoessl A. J. (2004a) Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127, 888899.
  • De La Fuente-Fernandez. R. Sossi V. Huang Z. Furtado S. Lu J. Q. Calne D. B. Ruth T. J. and Stoessl A. J. (2004b) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127, 27472754
  • Gardoni F. Picconi B. Ghiglieri V. Polli F. Bagetta V. Bernardi G. Cattabeni F. Di Luca M. and Calabresi P. (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci. 26, 29142922.
  • Gasser T. (2005) Genetics of Parkinson's disease. Curr. Opin. Neurol. 18, 363369.
  • Gerdeman G. L. Partridge J. G. Lupica C. R. and Lovinger D. M. (2003) It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26, 184192.
  • Gerfen C. R. Miyachi S. Paletzki R. and Brown P. (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22, 50425054.
  • Gerhardt G. A. and Burmeister J. J. (2000) Voltammetry in vivo for chemical analysis of the nervous system. In: Encyclopedia of Analytical Chemistry (MeyersR. A., ed.), pp. 710773. John Wiley and Sons Ltd, Chichester.
  • Grandas F. Galiano M. L. and Tabernero C. (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J. Neurol. 246, 11271133.
  • Graybiel A. M. (1995) Building action repertoires: memory and learning functions of the basal ganglia. Curr. Opin. Neurobiol. 5, 733741.
  • Greengard P. Nairn A. C. Girault J. A. Ouimet C. C. Snyder G. L. Fisone G. Allen P. B. Fienberg A. and Nishi A. (1998) The DARPP-32/protein phosphatase-1 cascade: a model for signal integration. Brain Res. Rev., 274284.
  • Guerra M. J. Liste I. and Labandeira-Garcia J. L. (1997) Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. Neuroreport 8, 34853488.
  • Hallett P. J. Dunah A. W. Ravenscroft P. Zhou S. Bezard E. Crossman A. R. Brotchie J. M. and Standaert D. G. (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48, 503516.
  • Hallett P. J. Spoelgen R. Hyman B. T. Standaert D. G. and Dunah A. W. (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci. 26, 46904700.
  • Hayashi Y. Shi S. H. Esteban J. A. Piccini A. Poncer J. C. and Malinow R. (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ. domain interaction. Science 287, 22622267.
  • Hiroi N., Marek G. J., Brown J. R., Ye H., Saudou F., Vaidya V. A., Duman R. S., Greenberg M. E. and Nestler E. J. (1998) Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures. J. Neurosci. 18, 69526962.
  • Hope B. T., Nye H. E., Kelz M. B., Self D. W., Iadarola M. J., Nakabeppu Y., Duman R. S. and Nestler E. J. (1994) Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13, 12351244.
  • Hurley M. J. Jackson M. J. Smith L. A. Rose S. and Jenner P. (2005) Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J. Neurosci. 21, 32403250.
  • Hyman S. E. and Malenka R. C. (2001) Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev. Neurosci. 2, 695703.
  • Jenner P. (2000) Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47, S90S99; discussion S99–104.
  • Kannari K. Yamato H. Shen H. Tomiyama M. Suda T. and Matsunaga M. (2001) Activation of 5-HT (1A) but not 5-HT (1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 76, 13461353.
  • Kerr J. N. and Wickens J. R. (2001) Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol. 85, 117124.
  • Konitsiotis S. Blanchet P. J. Verhagen Metman L. Lamers E. and Chase T. N. (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 15891595.
  • Konradi C. Westin J. E. Carta M. Eaton M. E. Kuter K. Dekundy A. Lundblad M. and Cenci M. A. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis 17, 219236.
  • Kuan W. L. and Barker R. A. (2005) New therapeutic approaches to Parkinson's disease including neural transplants. Neurorehabil Neural Repair 19, 155181.
  • Lee C. S. Cenci M. A. Schulzer M. and Bjorklund A. (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123, 13651379.
  • Lee W. Y. Lee E. A. Jeon M. Y. Kang H. Y. and Park Y. G. (2006) Vesicular monoamine transporter-2 and aromatic 1-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent 1-3,4-dihydroxyphenylalanine administration. Exp Neurol. 197, 215224.
  • Lee F. J. S. X. S. Pei L. Vukusic B. Chery N. Wang Y. Wang Y. T. and Niznik H. B. YuX.-M. and Liu F. (2002) Dual Regulation of NMDA Receptor Functions by Direct Protein–Protein Interactions with the Dopamine D1 Receptor. Cell 111, 219230.
  • Leenders K. L. Palmer A. J. Quinn N. Clark J. C. Firnau G. Garnett E. S. Nahmias C. Jones T. and Marsden C. D. (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J. Neurol. Neurosurg Psychiatry 49, 853860.
  • Leveque J. C. Macias W. Rajadhyaksha A et al. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20, 40114020.
  • Liu Y., Ishida Y., Shinoda K., Furukawa S. and Nakamura S. (2004) Opposite morphological responses of partially denervated cortical serotonergic and noradrenergic axons to repeated stress in adult rats. Brain Res. Bull. 64, 6774.
  • Liu Y., Ishida Y., Shinoda K. and Nakamura S. (2003) Interaction between serotonergic and noradrenergic axons during axonal regeneration. Exp Neurol. 184, 169178.
  • Lonart G. and Zigmond M. J. (1991) High glutamate concentrations evoke Ca (++)-independent dopamine release from striatal slices: a possible role of reverse dopamine transport. J. Pharmacol. Exp Ther 256, 11321138.
  • Lopez-Real A., Rodriguez-Pallares J., Guerra M. J. and Labandeira-Garcia J. L. (2003) Localization and functional significance of striatal neurons immunoreactive to aromatic 1-amino acid decarboxylase or tyrosine hydroxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res. 969, 135146.
  • Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci M. A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J. Neurosci. 15, 120132.
  • Lundblad M., Picconi B., Lindgren H. and Cenci M. A. (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis 16, 110123.
  • Maeda T., Nagata K., Yoshida Y. and Kannari K. (2005) Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered 1-DOPA. Brain Res. 1046, 230233.
  • Marsden C. D. (1990) Parkinson's disease. Lancet 335, 948952.
  • Mayeux R. (2003) Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81104.
  • Mazzella L., Yahr M. D., Marinelli L., Huang N., Moshier E. and Di Rocco A. (2005) Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on 1-dopa monotherapy. Parkinsonism Relat Disord 11, 151155.
  • Meissner W., Ravenscroft P., Reese R. et al. (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine. Neurobiol. Dis 22, 586598.
  • Melamed E., Hefti F. and Wurtman R. J. (1980) Nonaminergic striatal neurons convert exogenous 1-dopa to dopamine in parkinsonism. Ann. Neurol. 8, 558563.
  • Metman L. V., Konitsiotis S. and Chase T. N. (2000) Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 15, 38.
  • Metman L. V. and O'Leary S. T. (2005) Role of surgery in the treatment of motor complications. Mov Disord 20, S45S56.
  • Miller D. W. and Abercrombie E. D. (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem. 72, 15161522.
  • Morrish P. K., Sawle G. V. and Brooks D. J. (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119, 585591.
  • Moult P. R., Gladding C. M., Sanderson T. M., Fitzjohn S. M., Bashir Z. I., Molnar E. and Collingridge G. L. (2006) Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J. Neurosci. 26, 25442554.
  • Mouradian M. M., Heuser I. J., Baronti F., Fabbrini G., Juncos J. L. and Chase T. N. (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25, 523526.
  • Mouradian M. M., Juncos J. L., Fabbrini G. and Chase T. N. (1987) Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann. Neurol. 22, 475479.
  • Mouradian M. M., Juncos J. L., Fabbrini G., Schlegel J., Bartko J. J. and Chase T. N. (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann. Neurol. 24, 372378.
  • Nash J. E., Johnston T. H., Collingridge G. L., Garner C. C. and Brotchie J. M. (2005) Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. Faseb J. 19, 583585.
  • Nicola S. M., Surmeier J. and Malenka R. C. (2000) Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 23, 185215.
  • Nirenberg M. J., Liu Y., Peter D., Edwards R. H. and Pickel V. M. (1995) The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc. Natl Acad. Sci. U S A 92, 87738777.
  • Nomikos G. G., Arborelius L., Hook B. B., Hacksell U. and Svensson T. H. (1996) The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J. Neural Transm 103, 541554.
  • Nutt J. G. (1992) Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson's disease. In: Drug-Induced Movement Disorders (Lang, A. E. and Weiner, W. J., eds), pp. 281314. Futura Publishing Co, Inc., Mount Kisko.
  • Nutt J. G., Carter J. H., Lea E. S. and Woodward W. R. (1997) Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 12, 285292.
  • Nutt J. G. and Holford N. H. (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol. 39, 561573.
  • Nutt J. G., Woodward W. R., Carter J. H. and Gancher S. T. (1992) Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch. Neurol. 49, 11231130.
  • Nyholm D. and Aquilonius S. M. (2004) Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin. Neuropharmacol. 27, 245256.
  • Obeso J. A., Rodriguez-Oroz. M., Marin C., Alonso F., Zamarbide I., Lanciego J. L. and Rodriguez-Diaz. M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62, S17S30.
  • Oh J. D., Chartisathian K., Ahmed S. M. and Chase T. N. (2003) Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J. Neurosci. Res. 72, 768780.
  • Olanow C. W., Agid Y., Mizuno Y. et al. (2004b) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19, 9971005.
  • Olanow C. W., Damier P., Goetz. C. G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F. and Russ H. (2004a) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27, 5862.
  • Pardridge W. M. and Oldendorf W. H. (1975) Kinetic analysis of blood–brain barrier transport of amino acids. Biochim. Biophys. Acta 401, 128136.
  • Parish C. L., Stanic D., Drago J., Borrelli E., Finkelstein D. I. and Horne M. K. (2002) Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur J. Neurosci. 16, 787794.
  • Partridge J. G., Tang K. C. and Lovinger D. M. (2000) Regional and postnatal heterogeneity of activity-dependent long-term changes in synaptic efficacy in the dorsal striatum. J. Neurophysiol. 84, 14221429.
  • Pavon N., Martin A. B., Mendialdua A. and Moratalla R. (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59, 6474.
  • Pearce R. K., Banerji T., Jenner P. and Marsden C. D. (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than 1-dopa in the MPTP-treated marmoset. Mov Disord 13, 234241.
  • Peppe A., Dambrosia J. M. and Chase T. N. (1993) Risk factors for motor response complications in 1-dopa-treated parkinsonian patients. Adv. Neurol. 60, 698702.
  • Peter D., Liu Y., Sternini C., De Giorgio R., Brecha N. and Edwards R. H. (1995) Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 61796188.
  • Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M. A. and Calabresi P. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 6, 501506.
  • Porritt M. J., Batchelor P. E., Hughes A. J., Kalnins R., Donnan G. A. and Howells D. W. (2000) New dopaminergic neurons in Parkinson's disease striatum. Lancet 356, 4445.
  • Raevskii K. S., Gainetdinov R. R., Budygin E. A., Mannisto P. and Wightman M. (2002) Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation. Neurosci. Behav. Physiol. 32, 183188.
  • Rajput A. H., Fenton M. E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L. C., Senthilselvan A. and Hornykiewicz. O. (2002) Clinical-pathological study of levodopa complications. Mov Disord 17, 289296.
  • Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E. and Lang A. E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J. Med. 342, 14841491.
  • Reynolds J. N., Hyland B. I. and Wickens J. R. (2001) A cellular mechanism of reward-related learning. Nature 413, 6770.
  • Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J. F., Montastruc J. L. and Marsden C. D. (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55, 2330.
  • Robelet S., Melon C., Guillet B., Salin P. and Kerkerian-Le Goff L. (2004) Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J. Neurosci. 20, 12551266.
  • Sarre S., De Klippel N., Herregodts P., Ebinger G. and Michotte Y. (1994) Biotransformation of locally applied 1-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis. Naunyn Schmiedebergs Arch. Pharmacol. 350, 1521.
  • Schrag A. and Quinn N. (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123, 22972305.
  • Seibyl J. P., Marek K. L., Quinlan D et al. (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589598.
  • Sgambato V., Pages C., Rogard M., Besson M. J. and Caboche J. (1998) Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J. Neurosci. 18, 88148825.
  • Sgambato-Faure V., Buggia V., Gilbert F., Levesque D., Benabid A. L. and Berger F. (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 64, 936947.
  • Soghomonian J. J. (2006) L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. Eur J. Neurosci. 23, 23952403.
  • Stanic D., Finkelstein D. I., Bourke D. W., Drago J. and Horne M. K. (2003) Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J. Neurosci. 18, 11751188.
  • St-Hilaire M., Landry E., Levesque D. and Rouillard C. (2005) Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol. Dis. 20, 450460.
  • Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T. and Matsunaga M. (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631634.
  • Thomas M. J., Beurrier C., Bonci A. and Malenka R. C. (2001) Long-term depression in the nucleus accumbens: a neural correlate of behavioral sensitization to cocaine. Nat Neurosci. 4, 12171223.
  • Verhagen Metman L., Locatelli E. R., Bravi D., Mouradian M. M. and Chase T. N. (1997) Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48, 369372.
  • Wachtel S. R. and Abercrombie E. D. (1994) L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J. Neurochem. 63, 108117.
  • Wade L. A. and Katzman R. (1975) Synthetic amino acids and the nature of L-DOPA transport at the blood–brain barrier. J. Neurochem. 25, 837842.
  • Westin J. (2006a) Intracellular signalling and cellular plasticity in the basal ganglia in a rat model of L-DOPA induced dyskinesia. Doctoral dissertation, Lund University, Lund (Sweden).
  • Westin J. E., Lindgren H. S., Gardi J., Nyengaard J. R., Brundin P., Mohapel P. and Cenci M. A. (2006) Endothelial proliferation and increased blood–brain barrier permeability in the basal ganglia in a rat model of L-DOPA-induced dyskinesia. J. Neurosci., (in press)
  • Winkler C., Kirik D., Bjorklund A. and Cenci M. A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis 10, 165186.
  • Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290296.